Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 3Completed 2Active not recruiting 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Melanoma 10Carcinoma, Non-Small-Cell Lung 9Carcinoma, Renal Cell 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Colorectal Neoplasms 4Stomach Neoplasms 3Ovarian Neoplasms 3Neoplasms 2Lymphoma 2Head and Neck Neoplasms 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Pheochromocytoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1

Interventions

Cisplatin 18pembrolizumab 12Paclitaxel 9Carboplatin 9Radiotherapy 5Gemcitabine 4Fluorodeoxyglucose F18 4Colposcopy 4Brachytherapy 4fludarabine 3durvalumab 3Surveys and Questionnaires 3Radiation 3Flow Cytometry 3Cyclophosphamide 3Biopsy 3Bevacizumab 3toripalimab 2fludarabine phosphate 2atezolizumab 2aldesleukin 2adavosertib 2Zoledronic Acid 2Topotecan 2Nivolumab 2Neoadjuvant Therapy 2Microarray Analysis 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Interleukin-2 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Uterine Cervical Neoplasms × spartalizumab × Clear all
NCT04864782 2024-01-12

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Terminated
46 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡